Back to companies

Pharming Group NV: Premium Databases

Pharming Group NV Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Pharming Group NV Insights data

Headline Published Journalists
Showing 3 of 4 results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 08 Feb 2022 Lorem
Pharming’s prophylactic HAE strategy considers different routes of admin, dosing after FDA CRL, sources say; experts see BioCryst’s Phase II/III BCX7353 as competitive threat 18 Jan 2019 Jennifer C. Smith-Parker
Pharming seeks Latin American partner by YE14 to file and commercialise HAE drug Ruconest - CEO 23 Apr 2014 Jinan Harb
Santarus/Pharming’s Ruconest for hereditary angioedema likely to be FDA-approved but market traction minimal 25 Jul 2012 Jennifer C. Smith-Parker
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer